Changes in Candida albicans colonization and morphology under influence of voriconazole

Mycoses

Volumn 46, Issue 9-10, 2003, Pages 370-374

  Bernhardt, Hannelore ^a,b   Knoke, M ^a   Bernhardt, J ^a  

^a UNIVERSITY OF GREIFSWALD   (Germany)

^b NONE   (Germany)

Author keywords

Candida albicans; Colonization; Morphology; Voriconazole

Indexed keywords

OXYGEN; VORICONAZOLE;

ANIMAL CELL; ARTICLE; BIOFILM; CANDIDA ALBICANS; CANDIDIASIS; COLONY FORMATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; FLUORESCENCE; FLUORESCENCE MICROSCOPE; FUNGUS GROWTH; IN VITRO STUDY; METABOLIC REGULATION; MICROTITER PLATE ASSAY; MYCELIUM; NONHUMAN; PRIORITY JOURNAL; STAINING; TIME; VITAL STAIN;

ANTIFUNGAL AGENTS; BIOFILMS; CANDIDA ALBICANS; FLUORESCENT DYES; MICROSCOPY, FLUORESCENCE; MYCELIUM; NUCLEIC ACIDS; PYRIMIDINES; TRIAZOLES; VACUOLES;

ANIMALIA; CANDIDA; CANDIDA ALBICANS; FUNGI;

EID: 0242719881     PISSN: 09337407     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.0933-7407.2003.00908.x     Document Type: Article

References (14)

1. Millard PJ, Roth BL, Truong Thi H, Yue ST, Haugland RP. Development of the FUN-1 family of fluorescent probes for vacuole labelling and viability testing of yeasts. Appl Environm Microbiol 1997; 63: 2897-905.
2. Gow NAR, Brown AJP, Odds FC. Fungal morphogenesis and host invasion. Curr Opin Microbiol 2002; 5: 366-71.
3. Belanger P, Nast CC, Fratti R, Sanati H, Ghannoum M. Voriconazole (UK-109,496) inhibits the growth and alters the morphology of fluconazole-susceptible and -resistant Candida species. Antimicrob Agents Chemother 1997; 41: 1840-2.
4. Sheehan DJ, Hitchcock CA, Sibley CM. Current and emerging azole antifungal agents. Clin Microbiol Rev 1999; 12: 40-79.
5. Espinel-Ingroff A, Boyle K, Sheehan DJ. In vitro antifungal activities of voriconazole and reference agents as determined by NCCLS methods: review of the literature. Mycopathologia 2001; 150: 101-15.
6. Lass-Flörl C, Nagl M, Speth C, Ulmer H, Dierich MP, Würzner R. Studies of in vitro activities of voriconazole and itraconazole against Aspergillus hyphae using viability staining. Antimicrob Agents Chemother 2001; 45: 124-8.
7. Chandra J, Kuhn DM, Mukherjee PK, Hoyer LL, McCormick T, Ghannoum MA. Biofilm formation by the fungal pathogen Candida albicans: development, architecture, and drug resistance. J Bact 2001; 183: 5385-94.
8. Kuhn DM, Chandra J, Mukherjee PK, Ghannoum MA. Comparison of biofilms formed by Candida albicans and Candida parapsilosis on bioprosthetic surfaces. Infect Immun 2002; 70: 878-88.
9. Pina-Vaz C, Sansonetty F, Rodrigues AG, Costa-de-Oliveira S, Martinez-de-Oliveira J, Fonseca AF. Susceptibility to fluconazole of Candida clinical isolates determining by FUN-1 staining with flow cytometry and epifluorescence microscopy. J Med Microbiol 2001; 50: 375-82.
10. Bernhardt H, Zimmermann K, Knoke M. The continuous flow culture as an in vitro model in experimental mycology. Mycoses 1999; 42 (Suppl. 2): 29-32.
11. Zimmermann K, Bernhardt J, Knoke M, Bernhardt H. Influence of voriconazole and fluconazole on Candida albicans in long-time continuous flow culture. Mycoses 2002; 45 (Suppl. 1): 41-6.
12. Hawser SP, Douglas LJ. Resistance of Candida albicans biofilms to antifungal agents in vitro. Antimicrob Agents Chemother 1995; 39: 2128-31.
13. Baillie GS, Douglas LJ. Matrix polymers of Candida biofilms and their possible role in biofilm resistance to antifungal agents. J Antimicrob Chemother 2000; 46: 397-403.
14. Bernhardt H, Bernhardt J, Knoke M. Changes in Candida albicans colonization and morphology under influence of voriconazole. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy Abstract M-1505. 2002, 408.